Drugs / ISB 1442
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05427812 | Sep 2022 → Nov 2024 | refractory plasma cell neoplasm | Ichnos Sciences SA | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2024-04-30 | Ichnos Sciences SA | Results Corporate Presentation April 2024 iginnovate.com ↗
Overall, treatment with ISB 1442 is well tolerated. |
| 2024-03-08 | Ichnos Sciences SA | Results Ichnos Glenmark Innovation reports the publication in Nature Communications of the preclinical development of ISB 1442 bispecific antibody for Treatment of Relapsed/Refractory Multiple Myeloma iginnovate.com ↗
ISB 1442 exhibited superiority against daratumumab in cell lines in vitro, as well as in primary multiple myeloma patient’s samples ex vivo, and it also induced complete eradication of tumors in preclinical mouse models in vivo. |
| 2023-12-12 | Ichnos Sciences SA | Results Ichnos Sciences Delivers Strong Evidence for its Trio of Oncology Assets at ASH 2023 Annual Meetings iginnovate.com ↗
The studies showcased encouraging safety profiles, dose-dependent pharmacokinetics, and efficacy signals, marking significant progress in the fight against relapsed or refractory multiple myeloma. |
| 2023-07-07 | Ichnos Sciences SA | Regulatory Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001 iginnovate.com ↗
The US Food and Drug Administration grants orphan drug designation to ISB 1442 for the treatment of multiple myeloma |
| 2022-12-12 | Ichnos Sciences SA | Results Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting iginnovate.com ↗
Ichnos presentations include clinical and preclinical data on ISB 1342 (CD38xCD3), ISB 1442 (CD38xCD47) and an oral session on ISB 2001, its first TREAT ™ trispecific (BCMAxCD38xCD3) antibody |
| 2022-03-23 | Ichnos Sciences SA | Results Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting iginnovate.com ↗
The data being presented at AACR highlight the potential for ISB 1442, our first-in-class biparatopic CD38 x CD47 bispecific antibody, in multiple myeloma,” said Stefano Sammicheli, Ph.D., Director of Innate Cell Engagers, at Ichnos Sciences. |
| 2022-03-18 | Ichnos Sciences SA | Results Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference iginnovate.com ↗
President and Chief Executive Officer of Ichnos, Cyril Konto, M.D., shared the data in a presentation titled “Beyond the T cell: Co-targeting CD38 and CD47 with a 2+1 Biparatopic Multispecific Antibody” during an afternoon session of the conference. |
| 2021-12-16 | Ichnos Sciences SA | Results Scrip: Ichnos Gets Going with Almirall Deal, Multiple Myeloma Bispecifics Add Sheen iginnovate.com ↗
“ISB 1442 engages myeloid cells more prominently with blocking the CD47/SIRPα binding also known as ‘don’t eat me’ signal which allows killing of CD38 expressing tumor cells by macrophages,” Konto told Scrip. |
| 2021-12-11 | Ichnos Sciences SA | Results ISB 1442 Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma iginnovate.com ↗
ISB 1442 Shows Improved Tumor Growth Inhibition In Preclinical Model Compared To Daratumumab |
| 2021-12-11 | Ichnos Sciences SA | Results Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting iginnovate.com ↗
Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, today presented preclinical data that support the potential for ISB 1442, a first-in-class 2+1 biparatopic bispecific antibody that targets both CD38 and CD47, as a treatment for relapsed/refractory multiple myeloma and other CD38+ hematological malignancies. |
All press releases naming this drug 12 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISB 1442 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05427812 ↗ |
| Route | Subcutaneous | “administered ISB 1442 weekly by subcutaneous (SC) injection” NCT05427812 ↗ |